Search Results - "Muller, Carolyn Y"

R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis by Guo, Yuna, Kenney, S Ray, Muller, Carolyn Y, Adams, Sarah, Rutledge, Teresa, Romero, Elsa, Murray-Krezan, Cristina, Prekeris, Rytis, Sklar, Larry A, Hudson, Laurie G, Wandinger-Ness, Angela

“…Cdc42 (cell division control protein 42) and Rac1 (Ras-related C3 botulinum toxin substrate 1) are attractive therapeutic targets in ovarian cancer based on…”
Get full text

Innovation and Progress in Gynecologic Cancer Care: Faster than Ever by Muller, Carolyn Y., MD

Get full text

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study by Monk, Bradley J, Blessing, John A, Street, Daron G, Muller, Carolyn Y, Burke, James J, Hensley, Martee L

“…Abstract Objective To estimate activity and safety of trabectedin 1.5 mg/m2 IV over 24 hours every 3 weeks (1 cycle) in uterine leiomyosarcoma. Methods…”
Get full text

A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients by Guo, Yuna, Kenney, S Ray, Cook, Linda, Adams, Sarah F, Rutledge, Teresa, Romero, Elsa, Oprea, Tudor I, Sklar, Larry A, Bedrick, Edward, Wiggins, Charles L, Kang, Huining, Lomo, Lesley, Muller, Carolyn Y, Wandinger-Ness, Angela, Hudson, Laurie G

“…We previously identified the R-enantiomer of ketorolac as an inhibitor of the Rho-family GTPases Rac1 and Cdc42. Rac1 and Cdc42 regulate cancer-relevant…”
Get full text

High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer by Davies, Suzy, Holmes, Anna, Lomo, Lesley, Steinkamp, Mara P, Kang, Huining, Muller, Carolyn Y, Wilson, Bridget S

“…Ovarian cancer is the leading cause of death from gynecologic cancers in the United States. Failure may be due to variable expression and/or complex…”
Get full text

Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study by DE GEEST, Koen, BLESSING, John A, MORRIS, Robert T, DIANE YAMADA, S, MONK, Bradley J, ZWEIZIG, Susan L, MATEI, Daniela, MULLER, Carolyn Y, RICHARDS, William E

“…PURPOSE Ixabepilone (BMS-247550) is a microtubule-stabilizing epothilone B analog with activity in taxane-resistant metastatic breast cancer. The Gynecologic…”
Get full text

Pelvic floor disorders and sexual function in gynecologic cancer survivors: a cohort study by Rutledge, Teresa L., MD, Heckman, Seth R., MD, Qualls, Clifford, PhD, Muller, Carolyn Y., MD, Rogers, Rebecca G., MD

“…Objective The purpose of this study was to assess the prevalence of pelvic floor disorders and sexual function in survivors of gynecologic cancer. Study Design…”
Get full text

Normal Production of Human Chorionic Gonadotropin in Menopause by Cole, Laurence A, Sasaki, Yasushi, Muller, Carolyn Y

“…To the Editor: A positive test for the presence of human chorionic gonadotropin (hCG) before menopause is an indication of pregnancy. 1 A positive hCG test in…”
Get full text

Targeting the EGF Receptor for Ovarian Cancer Therapy by Zeineldin, Reema, Muller, Carolyn Y., Stack, M. Sharon, Hudson, Laurie G.

“…Ovarian carcinoma is the leading cause of death from gynecologic malignancy in the US. Factors such as the molecular heterogeneity of ovarian tumors and…”
Get full text

Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix by Castle, Philip E., Ashfaq, Raheela, Ansari, Faryal, Muller, Carolyn Y.

“…Heat Shock Proteins (HSPs) are molecular chaperons with multiple functions relating to cellular homeostasis. Primary, HSPs are expressed in response to…”
Get full text

Detection of perimenopause or postmenopause human chorionic gonadotropin: an unnecessary source of alarm by Cole, Laurence A., PhD, Khanlian, Sarah A., MPH, Muller, Carolyn Y., MD

“…Objective The normal pituitary production of human chorionic gonadotropin alongside luteinizing hormone, measurable in menopausal serum and urine was initially…”
Get full text

Gynecologic Cancer Care: Innovative Progress by Muller, Carolyn Y

Get full text

Analysis of genetic copy number changes in cervical disease progression by Policht, Frank A, Song, Minghao, Sitailo, Svetlana, O'Hare, Anna, Ashfaq, Raheela, Muller, Carolyn Y, Morrison, Larry E, King, Walter, Sokolova, Irina A

“…Cervical dysplasia and tumorigenesis have been linked with numerous chromosomal aberrations. The goal of this study was to evaluate 35 genomic regions…”
Get full text

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial by Liu, Joyce F, Brady, Mark F, Matulonis, Ursula A, Miller, Austin, Kohn, Elise C, Swisher, Elizabeth M, Cella, David, Tew, William P, Cloven, Noelle G, Muller, Carolyn Y, Bender, David P, Moore, Richard G, Michelin, David P, Waggoner, Steven E, Geller, Melissa A, Fujiwara, Keiichi, D'Andre, Stacy D, Carney, Michael, Alvarez Secord, Angeles, Moxley, Katherine M, Bookman, Michael A

“…Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed…”
Get full text

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study by Slomovitz, Brian M., Filiaci, Virginia L., Walker, Joan L., Taub, Michael C., Finkelstein, Karen A., Moroney, John W., Fleury, Aimee C., Muller, Carolyn Y., Holman, Laura L., Copeland, Larry J., Miller, David S., Coleman, Robert L.

“…Blocking the PI3K/AKT/mTOR pathway decreases resistance to hormonal therapy in endometrial carcinoma (EC). In this study, the aim was to assess the efficacy…”
Get full text

Intraoperative Lymphatic Mapping in Cervix Cancer Patients Undergoing Radical Hysterectomy: A Pilot Study by O'Boyle, John D., Coleman, Robert L., Bernstein, Steven G., Lifshitz, Samuel, Muller, Carolyn Y., Miller, David S.

“…Objective. Intraoperative lymphatic mapping and sentinel lymph node identification (SLN) have been increasingly evaluated in the treatment of a variety of…”
Get full text

Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy by Pennington, Kathryn P., Pugh, Stephanie L., Huh, Warner, Walker, Joan L., Jewell, Elizabeth, Havrilesky, Laura J., Carter, Jeanne, Muller, Carolyn Y., Drapkin, Ronny, Lankes, Heather A., Castellano, Tara, Zamorano, Abigail S., Blank, Stephanie V., Kachnic, Lisa A.

“…Most cases of ovarian cancer are diagnosed at an advanced stage, and long-term survival rates are low. Because no effective ovarian cancer screening has yet…”
Get full text

A pilot randomized control trial to evaluate pelvic floor muscle training for urinary incontinence among gynecologic cancer survivors by Rutledge, Teresa L, Rogers, Rebecca, Lee, Sang-Joon, Muller, Carolyn Y

“…Abstract Objectives We previously reported high rates of urinary incontinence among gynecologic cancer survivors and aimed to evaluate the effectiveness of a…”
Get full text

Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14 by Brown, Jubilee, Miller, Austin, Holman, Laura L., Backes, Floor, Nagel, Christa, Bender, David, Miller, David S., Powell, Matthew A., Westin, Shannon N., Bonebrake, Albert, Muller, Carolyn Y., Secord, Angeles Alvarez, Crane, Erin, Schorge, John, Tew, William P., Sood, Anil K., Bookman, Michael A., Aghajanian, Carol, Gershenson, David M.

“…To assess the efficacy and toxicity of paclitaxel and carboplatin (PC) compared to bleomycin, etoposide, and cisplatin (BEP) for treatment of newly diagnosed…”
Get full text

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study by Thaker, Premal H., Brady, William E., Lankes, Heather A., Odunsi, Kunle, Bradley, William H., Moore, Kathleen N., Muller, Carolyn Y., Anwer, Khursheed, Schilder, Russell J., Alvarez, Ronald D., Fracasso, Paula M.

“…•Recurrent EOC patients were treated with GEN-1 and pegylated liposomal doxorubicin.•Three had partial responses and five had stable disease of the 16…”
Get full text